Chelation Therapy Faces Decline as Evidence Shows Lack of Benefit
Chelation therapy, once promoted as a treatment for hardening of the arteries, is seeing a sharp decline in leverage following new research that confirms it does not work for cardiovascular conditions. According to a recent Dutch health news report, the number of practitioners offering chelation therapy in the Netherlands can now be counted on one hand, reflecting a broader trend of disuse as scientific scrutiny intensifies.
The therapy involves intravenous infusion of ethylenediaminetetraacetic acid (EDTA), a chemical that binds to metals and minerals in the bloodstream. Proponents have long claimed it removes calcium deposits from arteries, thereby improving blood flow. However, major clinical trials, including the large-scale TACT2 study funded by the U.S. National Institutes of Health, have found no significant benefit for patients with heart disease.
Web search results confirm that the TACT2 trial, published in recent years, showed chelation therapy did not reduce cardiovascular events compared to placebo. This aligns with earlier findings from the original TACT study, which also failed to demonstrate clear efficacy despite initial hopes. Medical authorities continue to classify chelation therapy as an unproven practice, particularly when marketed for arterial calcification.
One of the few remaining clinics offering the treatment in the Netherlands is Medi Reset Kliniek in Baarn, described in verified sources as still providing chelation infusions alongside vitamin supplements and laser therapy. The clinic is associated with Eduard Schweden, identified as an anthroposophic-based physician. However, even such outlets are noted as rare exceptions in a field where most practitioners have retired, passed away, or left the practice due to lack of evidence and patient demand.
Experts interviewed in past media reports, including a colleague of a chelation therapist featured in a Dutch television segment, have acknowledged that the mechanism of EDTA is not primarily about calcium removal. Instead, they suggest potential effects may involve heavy metal chelation, temporary hormonal influences on calcium balance, or antioxidant properties. Still, these theories remain unverified by rigorous clinical outcomes, and no major medical society endorses chelation therapy for atherosclerosis or related conditions.
The decline in chelation therapy reflects a broader shift in integrative medicine toward evidence-based approaches. While some patients continue to seek alternative treatments for chronic conditions, increasing transparency about treatment efficacy has led many to reconsider options lacking robust scientific support. Regulatory bodies in Europe and North America have not approved EDTA chelation for heart disease, and insurers typically do not cover the procedure when used for this purpose.
For individuals considering chelation therapy, healthcare providers recommend consulting with a licensed physician and reviewing guidance from trusted sources such as the American Heart Association or the European Society of Cardiology. These organizations emphasize proven strategies for vascular health, including lifestyle changes, statin therapy, blood pressure control, and diabetes management—all backed by decades of clinical research.
As the field moves forward, the focus remains on therapies validated through rigorous testing. Until such evidence emerges for chelation in cardiovascular care, its role is likely to remain marginal, confined to a small number of specialized clinics operating outside mainstream medical practice.
To stay informed about developments in cardiovascular treatments and evidence-based health practices, readers are encouraged to follow updates from reputable medical journals and public health institutions. Share your thoughts or experiences in the comments below, and help spread accurate information by sharing this article with others who may be considering unverified therapies.
Related reading